Related Experiment Video
Updated: Jul 17, 2026
Anterior High-Resolution Optical Coherence Tomography in the Diagnosis and Therapeutic Monitoring of Ocular Surface Squamous Neoplasia
Published on: August 9, 2024
Randomized controlled trial of topical mitomycin C for ocular surface squamous neoplasia: early resolution
1Queensland Eye Institute and University of Queensland, Brisbane, Australia. lawrie.hirst@pbf.org.au
Objective:
To assess the efficacy and safety of mitomycin C in the treatment of ocular surface squamous neoplasia.
Design:
Prospective, randomized, controlled, masked, single-center trial.
Participants:
Forty-eight consecutive patients with biopsy-proven noninvasive ocular surface squamous neoplasia.
Intervention:
Mitomycin C (0.4 mg/ml) or a placebo was administered as 1 drop 4 times a day for 3 weeks, with crossover of drops if there was no regression within 6 weeks.
Main Outcome Measures:
Successful treatment was measured as complete resolution of the neoplasia by slit-lamp examination within 6 to 8 weeks of treatment, with a secondary end point of histological resolution by 6 weeks.
Results:
None of 20 in the placebo group resolved clinically, whereas 24 of 26 in the mitomycin group resolved, giving a relative resolution rate of mitomycin versus placebo of 40.87 (95% confidence interval [CI], 1.01-1656.8). There were no complications. There was no statistical treatment effect on histological resolution, with a resolution rate of mitomycin versus placebo of 1.37 (95% CI, 0.34-5.42).
Conclusions:
Mitomycin C (0.4 mg/ml) eyedrops used 4 times a day for 3 weeks is an effective agent to cause early clinical resolution of noninvasive ocular surface squamous neoplasia.